Analysed ASCENTAGE PHARMA GR-ADR (AAPG:NASDAQ) News Sources
Ascentage Pharma Builds Momentum With 2 'Potential Blockbuster' Drugs, Oppenheimer Says
27-03-2026
yahoo.com
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
25-03-2026
yahoo.com
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026
18-03-2026
yahoo.com
Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026
11-03-2026
yahoo.com
A Look At Ascentage Pharma Group International’s Valuation After Recent Share Price Moves
09-03-2026
yahoo.com
BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
12-02-2026
yahoo.com
Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target
11-02-2026
yahoo.com
Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
09-02-2026
yahoo.com
What is the current price of ASCENTAGE PHARMA GR-ADR (AAPG:NASDAQ)?
The current price of ASCENTAGE PHARMA GR-ADR (AAPG:NASDAQ) is $25.33.
ASCENTAGE PHARMA GR-ADR (AAPG:NASDAQ) absolute price change since previous trading day?
The absolute price change of ASCENTAGE PHARMA GR-ADR (AAPG:NASDAQ) since the previous trading day is $-0.55.
ASCENTAGE PHARMA GR-ADR (AAPG:NASDAQ) percentage price change since previous trading day?
The percentage price change of ASCENTAGE PHARMA GR-ADR (AAPG:NASDAQ) since the previous trading day is -2.1252%.
What is the most recent average sentiment score for ASCENTAGE PHARMA GR-ADR (AAPG:NASDAQ)?
The most recent average sentiment score for ASCENTAGE PHARMA GR-ADR (AAPG:NASDAQ) is 81 out of 100.
What is the most recent average sentiment for ASCENTAGE PHARMA GR-ADR (AAPG:NASDAQ)?
The most recent sentiment for ASCENTAGE PHARMA GR-ADR (AAPG:NASDAQ) is .
SEC-8K** Filing Available For ASCENTAGE PHARMA GR-ADR (AAPG:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.